On Monday, Advaxis, Inc. (NASDAQ:ADXS)’s shares declined -3.94% to $18.28.
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, declared that it has designated Shelonitda S. Rose, M.D., as Vice President, Clinical Development. Dr. Rose brings to Advaxis more than 15 years of experience in medical oncology and hematology clinical research.
In her role as Vice President, Clinical Development, Dr. Rose will report to Advaxis’s Executive Vice President, Chief Medical Officer, David J. Mauro, MD, Ph.D., and will oversee clinical development programs for the Company’s Lm Technology™ platform. Advaxis has initiated three new clinical trials in 2015, counting a combination study involving ADXS-PSA and Merck’s PD-1 checkpoint inhibitor KEYTRUDA® (pembrolizumab). In addition, the Company anticipates to initiate six additional clinical trials by the end of year to evaluate its Lm Technology™ immunotherapy in cervical cancer, HPV-associated anal cancer and HER2 expressing solid tumors.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States.
Entergy Corporation (NYSE:ETR)’s shares dropped -0.12% to $72.28.
Entergy Corporation (ETR) declared that Robert Hall III has been named vice president, federal governmental affairs. Based in Entergy’s Washington, D.C., office, Hall’s responsibilities comprise developing and implementing the company’s stakeholder engagement strategies with elected officials and key policymakers.
Hall comes to Entergy from General Electric, where he served as the lead U.S. government affairs advocate for the company’s multiple energy technologies through his role as executive counsel. During his nearly 30 year career in Washington, Hall also worked at Dutko Worldwide as a senior vice president, as managing director of global government affairs at INVISTA and at Koch Industries as director, government affairs. He began his career as legislative counsel in the office of Sen. Sam Nunn.
Hall received his bachelor’s degree in political science from the University of Georgia and his Juris Doctor from the University of Georgia School of Law. He is a member of the State Bar of Georgia. Hall will report to Kimberly Despeaux, senior vice president, federal policy, regulatory and governmental affairs.
Entergy Corporation, together with its auxiliaries, engages in the electric power production and retail electric distribution operations in the United States. It operates in two segments, Utility and Entergy Wholesale Commodities. The Utility segment generates, transmits, distributes, and sells electric power in portions of Arkansas, Mississippi, Texas, and Louisiana, counting the City of New Orleans; and distributes natural gas.
At the end of Monday’s trade, Petmed Express Inc (NASDAQ:PETS)‘s shares dipped -2.48% to $16.54.
PetMed Express, Inc. (PETS) uncovered its financial results for the quarter ended June 30, 2015. Net income was $5.8 million, or $0.29 diluted per share, for the quarter ended June 30, 2015, compared to net income of $5.0 million, or $0.25 diluted per share, for the quarter ended June 30, 2014, a 16% increase to net income. Net sales for the quarter ended June 30, 2015 were $71.6 million, compared to $72.5 million for the quarter ended June 30, 2014, a decrease of 1.3%. The Company’s online sales for the quarter ended June 30, 2015 were approximately 81% of all sales, compared to 80% for the same quarter the prior year.
PetMed Express, Inc. and its auxiliaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats to retail customers. It offers non-prescription medications and supplies, counting flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventatives, arthritis, thyroid, diabetes, pain medications, antibiotics, and other specialty medications, in addition to generic substitutes.
Tsakos Energy Navigation Ltd. (NYSE:TNP), ended its Monday’s trading session with -2.40% loss, and closed at $9.77.
Tsakos Energy Navigation Ltd.(TNP), a leading crude, product and LNG tanker operator, will report earnings for the second quarter ended June 30, 2015, prior to the open of the market in New York on Friday, July 31, 2015.
That same morning, at 9:00 a.m. Eastern Time, TEN will host a conference call to review the results as well as management’s outlook for the business. The call, which will be hosted by TEN’s senior management, may contain information beyond what is included in the earnings press release.
Tsakos Energy Navigation Limited provides international seaborne crude oil and petroleum product transportation services worldwide. The company offers marine transportation services to national, major, and other independent oil companies and refiners under long, medium, and short-term charters. As of April 8, 2015, it had a fleet of 50 vessels, which comprised of 1 VLCC, 14 suezmaxes, 11 aframaxes, 9 panamaxes, 6 handymaxes, 8 handysizes, and 1 liquefied natural gas carrier. Tsakos Energy Navigation Limited has a planned partnership with Statoil for the crude oil tanker new buildings.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.